Free Trial
NASDAQ:SIBN

SI-BONE (SIBN) Stock Price, News & Analysis

$12.74
-0.24 (-1.85%)
(As of 10/23/2024 ET)

About SI-BONE Stock (NASDAQ:SIBN)

Key Stats

Today's Range
$12.56
$13.09
50-Day Range
$12.81
$17.01
52-Week Range
$11.76
$21.70
Volume
249,281 shs
Average Volume
379,787 shs
Market Capitalization
$531.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.67
Consensus Rating
Buy

Company Overview

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SI-BONE Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
75th Percentile Overall Score

SIBN MarketRank™: 

SI-BONE scored higher than 75% of companies evaluated by MarketBeat, and ranked 264th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SI-BONE has only been the subject of 3 research reports in the past 90 days.

  • Read more about SI-BONE's stock forecast and price target.
  • Earnings Growth

    Earnings for SI-BONE are expected to grow in the coming year, from ($0.89) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SI-BONE is -12.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SI-BONE is -12.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SI-BONE has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about SI-BONE's valuation and earnings.
  • Percentage of Shares Shorted

    4.05% of the outstanding shares of SI-BONE have been sold short.
  • Short Interest Ratio / Days to Cover

    SI-BONE has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in SI-BONE has recently increased by 2.42%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    SI-BONE does not currently pay a dividend.

  • Dividend Growth

    SI-BONE does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.05% of the outstanding shares of SI-BONE have been sold short.
  • Short Interest Ratio / Days to Cover

    SI-BONE has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in SI-BONE has recently increased by 2.42%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for SI-BONE this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for SIBN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added SI-BONE to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $349,879.00 in company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of SI-BONE is held by insiders.

  • Percentage Held by Institutions

    98.11% of the stock of SI-BONE is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about SI-BONE's insider trading history.
Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SIBN Stock News Headlines

Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
SIBN Sep 2024 17.500 call
See More Headlines

SIBN Stock Analysis - Frequently Asked Questions

SI-BONE's stock was trading at $20.99 at the start of the year. Since then, SIBN shares have decreased by 39.3% and is now trading at $12.74.
View the best growth stocks for 2024 here
.

SI-BONE, Inc. (NASDAQ:SIBN) announced its quarterly earnings results on Monday, August, 5th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. The company earned $39.97 million during the quarter, compared to analyst estimates of $38.95 million. SI-BONE had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 27.10%.

SI-BONE subsidiaries include these companies: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.

SI-BONE (SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE's top institutional investors include Essex Investment Management Co. LLC (0.41%), Diversified Trust Co (0.07%) and SG Americas Securities LLC (0.06%). Insiders that own company stock include Laura Francis, Anthony J Recupero, Anshul Maheshwari, Michael A Pisetsky, John Gordon Freund, Timothy E Davis Jr and Mika Nishimura.
View institutional ownership trends
.

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that SI-BONE investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/05/2024
Today
10/23/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:SIBN
Fax
N/A
Employees
350
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$22.67
High Stock Price Target
$32.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+77.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-43,340,000.00
Pretax Margin
-27.10%

Debt

Sales & Book Value

Annual Sales
$138.89 million
Book Value
$4.18 per share

Miscellaneous

Free Float
40,068,000
Market Cap
$531.13 million
Optionable
Optionable
Beta
1.22

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SIBN) was last updated on 10/24/2024 by MarketBeat.com Staff
From Our Partners